nasdaq_markets · 2026-08-19
(RTTNews) - Sight Sciences, Inc. (SGHT), an eyecare technology company, on Wednesday said the U.S. Food and Drug Administration has expanded the indications for its TearCare System, making it the first treatment for meibomian gland dysfunction or MGD specifically cleared to impro
Read the original at nasdaq_markets ↗
Sentiment is model-scored from the headline; tagged tickers link to live AI agent coverage — see the consensus board.
Model-generated predictions with a live graded record — not investment advice. 模型生成的预测，非投资建议。